alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
exv4w6






Exhibit 4.6









NOTICE OF CANCELLATION




To: THE
ROYAL BANK OF SCOTLAND PLC (as Agent)




Attention: Loans Admin Unit




The Royal Bank of Scotland plc

2nd Floor

Bankside 3

90-100 Southwark Street

London.

SE1 OSW




29 June 2010




VODAFONE GROUP PLC




US$4,315,000,000 Revolving Credit Facility dated 29 July 2008 (the Agreement)



We refer to the above Agreement and to the €4,000,000,000 Revolving Credit Facility Agreement to be
entered into by Vodafone Group Plc with The Royal Bank of Scotland plc as agent on or about the
date of this notice (the “New Facility Agreement”). Terms defined and references construed in the
Agreement have the same meaning and construction in this notice.



In accordance with Section 7.2 of the Agreement, we hereby give one Business Day’s written notice
of Vodafone’s intention to cancel the unutilised portion of the Total Commitments under the
Agreement in whole on or around 30 June 2010, provided that the New Facility Agreement is duly
signed and executed on such date.



This notice and any non-contractual obligations arising out of or in connection with it are
governed by English law.



Please acknowledge your acceptance of this notice by signing
below.




Yours faithfully






For and on behalf of

Vodafone Group Plc




We agree to the above:




	 	 	 

	 

For and on behalf of the Agent

	 	 
	The Royal Bank of Scotland plc
	 	 






Vodafone Group Plc

Vodafone House, The Connection, Newbury, Berkshire RG14 2FN, England

Telephone: +44 (0)1635 33251, Facsimile: +44 (0)1635 676746




Registered Office: Vodafone House, The
Connection, Newbury, Berkshire RG14 2FN, England. Registered in England No. 1833679
<PAGE>

                                                                    Exhibit 32.2

                    CERTIFICATION OF CHIEF FINANCIAL OFFICER
                       PURSUANT TO 18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

     In connection with the Annual Report of Metretek Technologies, Inc. (the
"Company") on Form 10-K for fiscal year ended December 31, 2005 as filed with
the Securities and Exchange Commission on the date hereof (the "Report"), I, A.
Bradley Gabbard, Executive Vice President and Chief Financial Officer of the
Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that:

     1.   The Report fully complies with the requirements of Section 13(a) or
          15(d) of the Securities Exchange Act of 1934, as amended; and

     2.   The information contained in the Report fairly presents, in all
          material respects, the financial condition and result of operations of
          the Company.


Date: March 22, 2006                    /s/ A. Bradley Gabbard
                                        ----------------------------------------
                                        A. Bradley Gabbard
                                        Executive Vice President and
                                        Chief Financial Officer

A signed original of this written statement required by Section 906 has been
provided to the Company and will be retained by the Company and furnished to the
Securities and Exchange Commission or its staff upon request.
```

[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[S. 4076 Introduced in Senate (IS)]

<DOC>

117th CONGRESS
  2d Session
                                S. 4076

   To protect firefighters from exposure to per- and polyfluoroalkyl 
                              substances.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                             April 25, 2022

Mrs. Gillibrand introduced the following bill; which was read twice and 
       referred to the Committee on Environment and Public Works

_______________________________________________________________________

                                 A BILL

 
   To protect firefighters from exposure to per- and polyfluoroalkyl 
                              substances.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``PFAS Firefighter Protection Act''.

SEC. 2. PROHIBITION ON FIREFIGHTING FOAM CONTAINING PFAS.

    (a) Prohibition.--Beginning on the date that is 2 years after the 
date of enactment of this Act, no person may manufacture, import, 
process, or distribute in commerce any aqueous film forming foam for 
use in training and firefighting that contains a per- or 
polyfluoroalkyl substance.
    (b) Violations.--A violation of subsection (a) shall be considered 
to be a violation of section 15(1) of the Toxic Substances Control Act 
(15 U.S.C. 2614(1)).

SEC. 3. DEADLINE TO PROHIBIT AQUEOUS FILM FORMING FOAM (AFFF) USE AT 
              AIRPORTS.

    Section 332 of the FAA Reauthorization Act of 2018 (49 U.S.C. 44706 
note) is amended by adding at the end the following:
    ``(c) Prohibition.--Not later than October 5, 2024, the 
Administrator, using the latest version of National Fire Protection 
Association 403, `Standard for Aircraft Rescue and Fire-Fighting 
Services at Airports', shall prohibit the use of fluorinated chemicals 
in firefighting foam at airports.''.
                                 <all>
```
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED BALANCE SHEET AND CONSOLIDATED STATEMENTS OF OPERATIONS FOUND ON
PAGES 4 THROUGH 7 OF THE COMPANY'S FORM 10-QSB FOR THE SIX MONTHS ENDED JUNE 30,
2000, AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               JUN-30-2000
<CASH>                                       4,890,987
<SECURITIES>                                         0
<RECEIVABLES>                                1,326,458
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                             6,607,667
<PP&E>                                       3,646,808
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                              22,492,845
<CURRENT-LIABILITIES>                        4,221,282
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                 14,196,261
<COMMON>                                        23,072
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                22,492,845
<SALES>                                      4,949,241
<TOTAL-REVENUES>                             4,949,241
<CGS>                                        1,971,785
<TOTAL-COSTS>                               14,974,212
<OTHER-EXPENSES>                             1,219,335
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             604,466
<INCOME-PRETAX>                           (11,244,306)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                              (32,329,345)
<EPS-BASIC>                                     (1.75)
<EPS-DILUTED>                                   (1.75)


</TABLE>
## Detailed Single Year Tables

- Individual Provisions
- Cost-of-Living Adjustment

### **Description of Proposed Provision:						A6: Starting December 2025, compute the COLA using the Consumer Price Index for the Elderly (CPI-E). We estimate this new computation will increase the annual COLA by about 0.2 percentage point, on average.**

### Financial Estimates for the OASDI Trust Fund Program

### Summarized Estimates
[Federal Register Volume 60, Number 34 (Tuesday, February 21, 1995)]
[Notices]
[Pages 9671-9672]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-4162]



=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF EDUCATION

[CFDA No.: 84.133D]


Office of Special Education and Rehabilitative Services National 
Institute on Disability and Rehabilitation Research; Notice Reinviting 
Applications and of a Pre-application Meeting for a New Award Under the 
Knowledge Dissemination and Utilization Program (D&U) for Fiscal Year 
(FY) 1995

    Purpose: On February 10, 1995, a notice was published in the 
Federal Register at 60 FR 8126 reinviting applications for new awards 
under the D&U program for fiscal year 1995 to train persons with rights 
and duties under the Americans with Disabilities Act (ADA). The date 
``April 11, 1995'' for which applications are available should be 
corrected to read.
    ``Applications Available: Feb. 21, 1995''.

For further Information Contact: Dianne Villines, U.S. Department of 
[[Page 9672]] Education, 600 Independence Avenue SW., Switzer Building, 
Room 3417, Washington, D.C. 20202. Telephone: (202) 205-9141. 
Individuals who use a telecommunications device for the deaf (TDD) may 
call the TDD number at (202) 205-8887.

    Dated: February 15, 1995.
Howard R. Moses,
Acting Assistant, Secretary for Special Education and Rehabilitative 
Services.
[FR Doc. 95-4162 Filed 2-17-95; 8:45 am]
BILLING CODE 4000-01-M
Exhibit
      32.2




CERTIFICATION




Pursuant
      to 18 U.S.C. Section 1350, the undersigned officer of Industrial Enterprises
      of
      America, Inc., a Nevada corporation (the “Company”), does hereby certify, to
      such officer’s knowledge, that the Company’s annual report on Form 10-QSB for
      the period ended June 30, 2005 (the “Form 10-QSB”) fully complies with the
      requirements of Section 13(a) or 15(d), as applicable, of the Securities
      Exchange Act of 1934 and that the information contained in the Form 10-QSB
      fairly presents, in all material respects, the financial condition and results
      of operations of the Company as of, and for, the periods presented in the Form
      10-QSB.




Dated:
      December 15, 2005




/s/ John Mazzuto


John
      Mazzuto, Chief Financial


Officer,
      Vice Chairman of the Board and Assistant


Secretary




The
      foregoing Certification is being furnished solely pursuant to 18 U.S.C. Section
      1350 and is not being filed as part of the Form 10-QSB or as a separate
      disclosure document.
**EXHIBIT32.2**

 

CERTIFICATIONPURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTEDPURSUANT TO

SECTION 906OF THE SARBANES-OXLEY ACT OF 2002

 

In connection withthe quarterly report of bebe stores, inc. (the “Company”) on Form 10-Q forthe quarter ended January 5, 2008, as filed with the Securities andExchange Commission on the date hereof (the “Report”), I, Walter Parks, ChiefFinancial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350,as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,that, based on my knowledge:

 

(1)     The Report fully complies with therequirements of section 13(a)  or 15(d) of the SecuritiesExchange Act of 1934; and

 

(2)     The information contained in the Reportfairly presents, in all material respects, the financial condition and resultsof operations of the Company.

 

 
| Dated: February 14, 2008 | /s/ Walter Parks            |   |
|-------------------------------|-----------------------------|--------|
|                          | Walter Parks                |
|                          | Chief Operating Officer and |
|                          | Chief Financial Officer     |

 

----
<PAGE>


                                                                      EXHIBIT 23



INDEPENDENT AUDITORS' CONSENT


We consent to the incorporation by reference in Registration Statement No.
333-90891 on Form S-8 and Registration Statement Nos. 33-71798, 33-93914 and
333-37955 on Form S-3 of Dura Pharmaceuticals, Inc. of our report dated
January 24, 2000, (March 20, 2000 as to the merger agreement with Spiros
Development Corporation II, Inc. described in Note 6), appearing in this
Annual Report on Form 10-K of Dura Pharmaceuticals, Inc. for the year ended
December 31, 1999.

/s/ DELOITTE & TOUCHE LLP


San Diego, California
March 28, 2000
NOT FOR PUBLICATION

UNITED STATES COURT OF APPEALS

FOR THE NINTH CIRCUIT

UNITED STATES OF AMERICA,

Plaintiff

- Appellee,

v.

SHAWN PATRICK MALARKEY,

Defendant

- Appellant. No. 17

- 35445

D.C. Nos. 9:16

- cv

- 00083

- DWM

9:11

- cr

- 00045

- DWM

- 1

MEMORANDUM *

Appeal from the United States District Court

for the District of Montana

Donald W. Molloy, District Judge, Presiding

Submitted October 22, 2019 **

Portland, Oregon

Before: FARRIS, BEA, and CHRISTEN, Circuit Judges.

Shawn Patrick Malarkey appeals the district court’s order denying his

motion to vacate his sentence imposed in connection with Count Two of the

indictment: use of a firearm during a crime of violence under 18 U.S.C.

§ 924(c)( 1)(A), where the predicate “crime of violence” is armed robbery

* This disposition is not appropriate for publication and is not precedent

except as provided by Ninth Circuit Rule 36

- 3.

** The panel unanimously concludes this case is suitable for decision

without oral argument. See Fed. R. App. P. 34(a)(2). 

# FILED

DEC 2 2019

MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS2

involving controlled substances under 18 U.S.C. § 2118(c)(1). We affirm.

For the reasons set forth in our concurrently filed opinion in United States v.

Burke , No. 17

- 35446, we hold that armed robbery involving controlled substances

qualifies as a crime of violence under § 924(c) (3)(A)

.

AFFIRMED.
EXHIBIT 32.1

CERTIFICATION PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(18 U.S.C. SECTION 1350)

In connection with the quarterly report of Golden State Vintners, Inc., a Delaware corporation (the "Company") on Form 10-Q for the quarterly period ended
March 31, 2004 as filed with the Securities Exchange Commission (the "Report"), I, Jeffrey B. O'Neill, Chief Executive Officer of the Company, certify, pursuant to Section 906 of the
Sarbannes-Oxley Act of 2002 (18 U.S.C. Section 1350), that to my knowledge:

(1)   The
Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)   The
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

|/s/JEFFREY B. O'NEILLJeffrey B. O'Neill
Chief Executive Officer
May 13, 2004 |  | 
|---------------------------------------------------------------------------- |  | 
|                                                                             |  | 

---



QuickLinks
NOTE: This order is nonprecedential. 

muiteb ~tate% «ourt of §ppeaI% 

for tbe jf eberaI «ircuit 

DURAMED PHARMACEUTICALS, INC., 

Plaintiff-Appellant, 

v. 

WATSON LABORATORIES, INC., 

Defendant-Appellee. 

2011-1438 

Appeal from the United States District Court for the 

District of Nevada in case no. 08-CV-0116, Judge Larry R. 

Hicks. 

ON MOTION 

Before LOURIE, LINN, AND DYK, Circuit Judges. 

LOURIE, Circuit Judge. 

ORDER 

Duramed Pharmaceuticals, Inc. (Duramed) submits a 

motion for a temporary injunction to prevent Watson 

Laboratories, Inc. (Watson) from launching a generic 

version of its patented drug, pending disposition of its 
DURAMEDPHARMA v. WATSON LABS 2 

appeal, and seeks an expedited briefing schedule. Watson 

opposes. Duramed replies. 

Rule 8(a)(1)(C)(2) of the Federal Rules of Appellate 

Procedure authorizes this court to grant an injunction 

pending appeaL Similar to a motion to stay a judgment or 

injunction pending appeal, which is authorized under this 

same rule, our determination is governed by four factors, 

the first two of which are the most critical: (1) whether 

the movant has made a strong showing of likelihood of 

success on the merits; (2) whether the movant will be 

irreparably injured absent a stay; (3) whether issuance of 

the stay will substantially injure the other parties interested in the proceeding; and (4) where the public interest 

lies. Hilton v. Braunskill, 481 U.s. 770, 776 (1987). 

Without prejudicing the ultimate disposition of this 

case by a merits panel, we conclude based upon the papers submitted that Duramed has not established that it 

is entitled to the extraordinary relief of a • temporary 

injunction pending this appeaL 

Accordingly, 

IT Is ORDERED THAT: 

(1) The motion for a temporary injunction is denied. 

(2) The motion for expedited briefing is granted. 

Duramed's opening brief shall be filed within seven days 

of the issuance of this order. Watson's brief shall be due 

fourteen days after the filing of Duramed's opening brief. 

Duramed's reply brief and the joint appendix shall be due 

seven days after the filing of Watson's brief. 
3 DURAMEDPHARMA V. WATSON LABS 

JUL 272011 

Date 

cc: Vernon M. Winters, Esq. 

Mark T. Jansen, Esq. 

s23 

FOR THE COURT 

lsI Jan Horbaly 

Jan Horbaly 

Clerk 

I.S. couJ~~~~P£ALS FOR 

THE FEDERAL CIRCUIT 

JUL 272011 

JANHORBAlY 

ClEAK
NOT FOR PUBLICATION

UNITED STATES COURT OF APPEALS

 FOR THE NINTH CIRCUIT

UNITED STATES OF AMERICA,

Plaintiff-Appellee,

 v.

APOLINAR CRUZ-CRUZ, a.k.a. Poli,

Defendant-Appellant.

No. 15-30276

D.C. No. 2:13-cr-00049-RSL

MEMORANDUM*

Appeal from the United States District Court

for the Western District of Washington

Robert S. Lasnik, District Judge, Presiding

Submitted December 14, 2016** 

Before: WALLACE, LEAVY, and FISHER, Circuit Judges.

Apolinar Cruz-Cruz appeals from the district court’s judgment and

challenges the denial of his motion to withdraw his guilty plea. We have

jurisdiction under 28 U.S.C. § 1291. We affirm.

FILED

DEC 19 2016

MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS

* This disposition is not appropriate for publication and is not precedent

except as provided by Ninth Circuit Rule 36-3.

** The panel unanimously concludes this case is suitable for decision

without oral argument. See Fed. R. App. P. 34(a)(2).
The government argues that this appeal should be dismissed based on the

appeal waiver contained in the parties’ plea agreement. Because the magistrate

judge only advised Cruz-Cruz of the waiver of his right to appeal his sentence, not

the waiver of his right to appeal his conviction, we conclude that this appeal is not

barred by the appeal waiver. See Fed. R. Crim. P. 11(b)(1)(N); United States v.

Brizan, 709 F.3d 864, 866 (9th Cir. 2013).

Cruz-Cruz contends that the district court erred in determining that his

allegations of legal advice during plea negotiations did not constitute a “fair and

just reason” for withdrawing his guilty plea. We disagree. Cruz-Cruz was aware

of the allegedly deficient legal advice at the time of his guilty plea. See United

States v. Mayweather, 634 F.3d 498, 506 (9th Cir. 2010) (“We have never held that

[Federal Rule of Criminal Procedure 11(d)(2)(B)] also embraces circumstances

known to a defendant at the time of the guilty plea, and we decline to do so now.”). 

Further, Cruz-Cruz failed to demonstrate that different legal advice plausibly

would have motivated a reasonable person in his position not to plead guilty. See

United States v. Bonilla, 637 F.3d 980, 983 (9th Cir. 2011).

We reject Cruz-Cruz’s argument, raised for the first time on appeal, that the

district court plainly erred in not allowing him to withdraw his guilty plea on the

basis of a Rule 11 error during the plea colloquy. See United States v. Jimenez2 15-30276
Dominguez, 296 F.3d 863, 866-67 (9th Cir. 2002) (a defendant raising a Rule 11

error for the first time on appeal must demonstrate plain error, including that any

error affected his substantial rights).

AFFIRMED.

3 15-30276
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Dental and Craniofacial Research Special Emphasis Panel; Review of Applications for NIDCR Clinical Trial or Biomarker Clinical Validation Study Planning Grant (R34).                    

*Date:*                         March 11, 2016.                    

*Time:*                         12:00 p.m. to 1:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892.                    

*Contact Person:*                         Victor Henriquez, Ph.D., Scientific Review Officer, DEA/SRB/NIDCR, 6701 Democracy Blvd., Room 668, Bethesda, MD 20892-4878, 301-451-2405,                         *henriquv@nidcr.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and Disorders Research, National Institutes of Health, HHS)

Dated: February 11, 2016.

David Clary,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2016-03236 Filed 2-17-16; 8:45 am]

 BILLING CODE 4140-01-P